Do statins delay motor progression of Huntington’s disease?

Statin use and delayed onset of Huntington’s disease.

Schultz JL, Nopoulos PC, Killoran A, Kamholz JA.

Mov Disord 2019; 34:281-285.

Abstract

BACKGROUND:

There is evidence to suggest that 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) may be beneficial in Huntington’s disease (HD).

OBJECTIVE:

This study aimed to determine if statin use was associated with delayed motor diagnosis in participants with premotor HD.

METHODS:

Among premotor HD participants from the Enroll-HD database, statin users  were propensity score matched with statin nonusers based on cytosine-adenine-guanine-age product score, cytosine-adenine-guanine repeat length, baseline age, sex, and region. A Cox regression survival analysis compared the annualized hazard ratio (HR) of receiving a motor diagnosis between the 2 groups.

RESULTS:

The annualized HR of progressing to an HD motor diagnosis was lower in the statin users (n = 89) when compared with the statinnonusers (n = 89; HR = 0.27 [95% CI 0.18-0.50], P < .0001).

CONCLUSIONS:

In patients with premotor HD, statin use was associated with a delayed motor diagnosis of HD. Further studies are warranted to investigate if statins would be an effective disease-modifying therapy for HD.

This paper is cited in the neurochecklist:

Huntington’s disease (HD): clinical features

Abstract link

次のアドレスからこのファイルで使用している画像を取得できますURL., CC BY-SA 2.1 jp, Link
Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s